Novartis: Diabetic Retinopathy trials

The registry lists 15 Diabetic Retinopathy studies with Novartis as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 2 3Phase 3 8Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT04058067Phase 3Results posted
• Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular EdemaCompletedNCT03927690Phase 2Results posted
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03917472Phase 3Results posted
• Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03481634Phase 3Results posted
• Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula EdemaCompletedNCT02366468Phase 4Results posted
• An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.CompletedNCT01908816Phase 3Results posted
• Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)CompletedNCT01594281Phase 2Results posted
• Efficacy of Aliskiren in the Treatment of Diabetic Macular EdemaTerminatedNCT00768040Phase 2Results posted
• Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKiaCompletedNCT02232503
• Ranibizumab "Treat and Extend" in Diabetic Macular EdmaCompletedNCT01297569Phase 4
• Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial TreatmentCompletedNCT01257815Phase 4
• Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyTerminatedNCT00248157Phase 3
• Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyTerminatedNCT00248131Phase 3
• Octreotide Acetate in Microspheres in Patients With Diabetic RetinopathyCompletedNCT00131144Phase 3
• Octreotide Acetate in Microspheres in Patients With Diabetic RetinopathyCompletedNCT00130845Phase 3